These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20358434)

  • 41. Arousal in obstructive sleep apnoea patients is associated with ECG RR and QT interval shortening and PR interval lengthening.
    Smith JH; Baumert M; Nalivaiko E; McEvoy RD; Catcheside PG
    J Sleep Res; 2009 Jun; 18(2):188-95. PubMed ID: 19645965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flexible Bayesian quantile regression for independent and clustered data.
    Reich BJ; Bondell HD; Wang HJ
    Biostatistics; 2010 Apr; 11(2):337-52. PubMed ID: 19948746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical utility of QT interval assessment in diabetes.
    Veglio M; Chinaglia A; Cavallo Perin P
    Diabetes Nutr Metab; 2000 Dec; 13(6):356-65. PubMed ID: 11232762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions.
    Wadhani N; Sarma JS; Singh BN; Radzik D; Gaud C
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):184-90. PubMed ID: 17056831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An efficient and robust analysis of covariance model for baseline adjustment in parallel-group thorough QT/QTc studies.
    Lu K
    Stat Med; 2013 Jun; 32(14):2406-18. PubMed ID: 22996035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A flexible class of models for data arising from a 'thorough QT/QTc study'.
    Anand SP; Ghosh SK
    Pharm Stat; 2011; 10(2):122-7. PubMed ID: 20306546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al.
    Wang Y; Garnett C
    J Biopharm Stat; 2010 May; 20(3):689-92; author reply 693-7. PubMed ID: 20358447
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.
    Piotrovsky V
    AAPS J; 2005 Oct; 7(3):E609-24. PubMed ID: 16353940
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Further discussion on the design and analysis of thorough QTc clinical trials: guest editors' notes.
    Tsong Y; Zhang J
    J Biopharm Stat; 2010 May; 20(3):493-6. PubMed ID: 20358431
    [No Abstract]   [Full Text] [Related]  

  • 51. Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.
    Malik M; Garnett C; Hnatkova K; Johannesen L; Vicente J; Stockbridge N
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):491-503. PubMed ID: 29651591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regression analysis with covariates that have heteroscedastic measurement error.
    Guo Y; Little RJ
    Stat Med; 2011 Aug; 30(18):2278-94. PubMed ID: 21590792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reference regions for beat-to-beat ECG data.
    Crimin KS; Emerson JW; Muirhead RJ
    Pharm Stat; 2011; 10(2):162-8. PubMed ID: 20568100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of QT interval using a linear model in individual cynomolgus monkeys.
    Koga T; Kuwano K; Kito G; Kanefuji K
    J Pharmacol Toxicol Methods; 2007; 55(3):248-53. PubMed ID: 17141531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A semiparametric probit model for case 2 interval-censored failure time data.
    Lin X; Wang L
    Stat Med; 2010 Apr; 29(9):972-81. PubMed ID: 20069532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A tolerance interval approach for assessment of agreement with left censored data.
    Choudhary PK
    J Biopharm Stat; 2007; 17(4):583-94. PubMed ID: 17613643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.
    Sun GG; Quan H
    J Biopharm Stat; 2010 May; 20(3):683-7; author reply 688. PubMed ID: 20358445
    [No Abstract]   [Full Text] [Related]  

  • 58. Model averaging for robust assessment of QT prolongation by concentration-response analysis.
    Dosne AG; Bergstrand M; Karlsson MO; Renard D; Heimann G
    Stat Med; 2017 Oct; 36(24):3844-3857. PubMed ID: 28703360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reader variability in QT measurement due to measurement error and variability in leads selection: a simulation study comparing 2-way vs. 3-way interaction ANOVA model.
    Natekar M; Karnad DR; Salvi V; Ramasamy A; Kerkar V; Panicker GK; Kothari S
    J Electrocardiol; 2014; 47(2):140-3. PubMed ID: 24209499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of assay measurement error on parameter estimation in concentration-QTc interval modeling.
    Bonate PL
    Pharm Stat; 2013; 12(3):156-64. PubMed ID: 23606626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.